Galecto, Inc. (GLTO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

75 STATE STREET BOSTON, MA 02109

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. The Company's team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases.

Data as of 2021-09-19 13:31:46 -0400
Market Cap101.805 Million Shares Outstanding25.262 Million Avg 30-day Volume88.505 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low17.99 / 3.8 Next Earnings Date2021-11-04 Price to Cash FLow (P/CF) -10.3915
Data provided by IEX Cloud
View SEC Filings from GLTO instead.

View recent insider trading info

Funds Holding GLTO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GLTO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

3 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FREVE JONATHAN CHIEF FINANCIAL OFFICER

  • Officer
5,000 2021-08-18 4

LINDMARK BERTIL CHIEF MEDICAL OFFICER

  • Officer
2,000 2021-06-28 3

SCHAMBYE HANS T. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
42,928 2021-06-24 4

WINSLOW GARRETT GENERAL COUNSEL

  • Officer
2,000 2021-06-23 3

GOLDFISCHER CARL

  • Director
18,000 2021-05-26 3

KHUONG CHAU QUANG

  • Director
18,000 2021-05-26 3

DALLAS JAYSON DONALD ALEXANDER

  • Director
18,000 2021-05-26 3

PRENER ANNE

  • Director
18,000 2021-05-26 3

PEDERSEN ANDERS CHIEF OPERATING OFFICER

  • Officer
0 2021-01-05 3

ORBIMED ADVISORS LLC

ORBIMED ADVISORS ISRAEL II LTD

ORBIMED ISRAEL GP II, L.P.

ORBIMED CAPITAL GP VII LLC

ORBIMED GENESIS GP LLC

  • Director
  • 10% Owner
6,681,390 2020-11-02 2

CHRISTGAU STEPHAN

  • Director
546,136 2020-11-02 2

NOVO HOLDINGS A/S

  • 10% Owner
2,497,791 2020-11-02 2

MUNSHI AMIT

  • Director
4,793 2020-11-02 2

SHAPIRO DAVID

  • Director
0 2020-10-28 1

MOLLER SOREN

  • Director
0 2020-10-28 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

FREVE JONATHAN - Officer CHIEF FINANCIAL OFFICER

2021-08-19 16:00:16 -0400 2021-08-18 P 3,000 $3.92 a 5,000 direct 7.5795 6.357 9.291 3 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
GALECTO INC GLTO 2021-09-24 18:15:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 17:45:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 17:15:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 16:45:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 16:15:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 15:45:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 15:15:04 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 14:45:02 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 14:15:02 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 13:45:02 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 13:15:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-24 12:45:03 UTC -24.9004 24.9704 200000
GALECTO INC GLTO 2021-09-23 22:15:03 UTC -24.9004 24.9704 250000
GALECTO INC GLTO 2021-09-23 21:45:03 UTC -24.9004 24.9704 250000
GALECTO INC GLTO 2021-09-23 21:15:03 UTC -24.9004 24.9704 250000
GALECTO INC GLTO 2021-09-23 20:45:03 UTC -24.9004 24.9704 250000
GALECTO INC GLTO 2021-09-23 20:15:03 UTC -24.9004 24.9704 250000
GALECTO INC GLTO 2021-09-23 19:45:03 UTC -24.9004 24.9704 250000
GALECTO INC GLTO 2021-09-23 19:15:03 UTC -24.9004 24.9704 250000
GALECTO INC GLTO 2021-09-23 18:45:04 UTC -24.9004 24.9704 250000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments